诉讼案件 - 某些投资者对Actinium Pharmaceuticals Inc (NYSE: ATNM)提起证券集体诉讼 指控公司违反证券法 [1][2] - 诉讼涉及2022年10月前购入并仍持有该公司股票的投资者 [1] 指控内容 - 原告指控公司未披露Sierra试验数据不符合FDA关于Iomab-B生物制剂许可申请(BLA)的审批指南 [2] - 公司提供的长期随访数据分析显示总体生存率改善趋势 但原告认为仍无法满足FDA审批要求 [2] - 原告称FDA可能拒绝审查Iomab-B BLA申请 或基于现有数据不予批准 [2] - 公司此前关于业务运营和发展前景的积极陈述被指控存在重大误导性 [2] 投资者参与方式 - 符合资格的投资者可通过邮件[email protected]或电话+1(858)779-1554联系股东基金会 [1][3] - 股东基金会提供证券集体诉讼监测和索赔申报服务 但非律师事务所 [3]

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Actinium investors who were adversely affected by alleged securities fraud between October 31, 2022 and August 2, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/actinium-law ...

NEW YORK, April 29, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Actinium investors who were adversely affected by alleged securities fraud between October 31, 2022 and August 2, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/actinium-lawsuit-s ...

NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM). Shareholders who purchased shares of ATNM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/actinium-loss-submission-form/?id=145068&from=3 CLASS PERIOD: Octobe ...

核心观点 - ATNM-400在治疗前列腺癌模型中显示出比Pluvicto更高的疗效，单次40 µCi/kg剂量可实现99.8%的肿瘤生长抑制[1][6] - ATNM-400靶向非PSMA受体，该受体在转移性去势抵抗性前列腺癌(mCRPC)中高表达且不受Pluvicto治疗影响[4][6] - ATNM-400在Pluvicto治疗失败后仍能持续抑制肿瘤生长，展现对耐药模型的强效抗肿瘤活性[3][6] 药物特性 - ATNM-400采用Ac-225放射性同位素，比Pluvicto的Lu-177更具效力，能通过双链DNA断裂实现不可逆细胞杀伤[4][10] - 生物分布分析显示ATNM-400在肿瘤中持续摄取至216小时，48小时内从血液中快速清除且对关键器官无毒性[10] - 两种剂量水平下均表现良好耐受性，无显著毒性反应[1][10] 临床前数据 - 在22Rv1前列腺癌模型中，ATNM-400比Pluvicto显著减少肿瘤体积(p < 0.0001)[2][5] - 对Pluvicto耐药肿瘤模型仍显示强劲抗肿瘤活性和生长抑制[3][6] - 单剂量40 µCi/kg实现近100%肿瘤生长抑制，支持其作为替代方案的潜力[1][6] 市场与竞争 - Pluvicto(诺华销售)2024年销售额达13.9亿美元，ATNM-400作为非PSMA靶向疗法具备差异化优势[1][4] - Ac-225同位素具有更短路径长度，可能减少脱靶效应，增强治疗精准度[4] - 公司拥有230项专利，涵盖Ac-225同位素生产等关键技术[8] 研发管线 - 除ATNM-400外，公司主要候选药物Actimab-A针对AML，已展示与CLAG-M联用的高完全缓解率[8] - 与NCI合作开展Actimab-A三联疗法(联合Venetoclax和ASTX-727)的临床试验[8] - 开发Iomab-ACT作为下一代细胞基因疗法预处理方案[8]

诉讼背景 - Gross Law Firm向Actinium Pharmaceuticals Inc (NYSE: ATNM)股东发布集体诉讼通知 鼓励在特定期间购入股票者联系该事务所[1] - 诉讼涉及期间为2022年10月31日至2024年8月2日[2] - 股东参与截止日期为2025年5月27日[3] 指控内容 - 公司被指控在诉讼期间发布重大虚假或误导性陈述 且未披露关键信息[2] - 公司Phase 3 Sierra试验数据不符合FDA对靶向放疗药物Iomab-B生物制剂许可申请(BLA)的审批指南要求[2] - 公司向FDA提供的长期随访等补充分析未能证明总体生存率(OS)改善趋势 不符合FDA对Iomab-B BLA的审批标准[2] - FDA可能拒绝审查Iomab-B BLA申请 或否决当前形式的申请[2] - 公司关于业务运营及前景的正面陈述存在重大误导性且缺乏合理依据[2] 参与程序 - 股东需通过指定链接完成注册以参与集体诉讼[3] - 注册后将通过投资组合监控软件接收案件进展更新[3] - 申请成为首席原告的截止日期为2025年5月27日[3] - 参与诉讼无需支付任何费用或承担义务[3] 律师事务所资质 - Gross Law Firm为全美知名集体诉讼律师事务所 专注于维护因欺诈及非法商业行为遭受损失的投资者权益[4] - 该事务所致力于确保企业遵守负责任商业实践和良好企业公民准则[4] - 主要针对因公司虚假陈述或重大信息遗漏导致股价人为膨胀造成的投资损失进行追偿[4]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Actinium To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Actinium between October 31, 2022 and August 2, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- Faru ...

NEW YORK, April 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Actinium investors who were adversely affected by alleged securities fraud between October 31, 2022 and August 2, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/actinium-lawsuit-s ...

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM). Shareholders who purchased shares of ATNM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/actinium-loss-submission-form/?id=144420&from=3 CLASS PERIOD: Octobe ...

NEW YORK  , April 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Actinium investors who were adversely affected by alleged securities fraud between October 31, 2022 and August 2, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/actinium-lawsuit ...